According to Bloomberg, the twelve research firms that follow Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) have reportedly rated the company “Hold” as its overall recommendation to its clients. The company reportedly gave this rating as part of its overall recommendation to its clients. Two research firms have assigned a rating of “sell” to the company’s share price, while ten research firms have assigned a rating of “hold,” and ten research firms have assigned a rating of “buy” to the stock.
The brokerage firms that have commented on the company in the prior year have an average target price of $15.33 for the company’s stock for the subsequent 12 months. This price target was determined after considering the company’s historical performance. In a few of the most recent investigations that they have conducted, research analysts have concentrated their attention on DCPH. On Monday, Cowen published a report announcing that it would begin covering shares of Deciphera Pharmaceuticals. This news came about as a result of the company’s previous coverage. They recommended that investors “outperform” the stock. In a report that was released on Friday, August 5th, JMP Securities raised their rating on shares of Deciphera Pharmaceuticals from “market perform” to “outperform” in a report that was released on August 5th. They set their target price on the stock at $23.00. In a research note released on Friday, August 5th, HC Wainwright reaffirmed its “buy” rating on shares of Deciphera Pharmaceuticals and increased its price objective for the company’s stock from $15.00 to $20.00 in a research note. In addition, they increased the price at which they anticipate the stock will reach from $15.00 to $20.00. On Monday, Cowen published a report announcing that it would begin covering shares of Deciphera Pharmaceuticals.
This news came about as a result of the company’s previous coverage. They believe that the company will “outperform” its current expectations, and their price objective for the stock is $25.00. In a research note published on Friday, August 5th, SVB Leerink changed their rating on Deciphera Pharmaceuticals from “neutral” to “outperform” and raised their price target for the company’s stock from $15.00 to $21.00. This was the company’s most recent distinction, but it certainly did not come in last place. When trading on DCPH started on Tuesday, the price was $15.76 a share. The company has a price-to-earnings ratio of -3.68, a beta of 1.11, and a market value of $1.05 billion. Additionally, the company has a negative beta. Over the previous year, the lowest price paid for Deciphera Pharmaceuticals was $6.51, while the highest price for the company was $17.33. The simple moving average for the stock for the past 50 days is $14.12, and the simple moving average for the past 200 days is $11.31. On August 4th, the most recent quarterly earnings report for Deciphera Pharmaceuticals (NASDAQ: DCPH) was made accessible to the general public for their perusal. During the period under consideration, the firm reported earnings of $0.60 per share, which was $0.05 higher than the consensus estimate of $0.65 per share supplied by industry analysts. The amount of money brought in during the quarter was $32.49 million, which is greater than the prediction made by analysts, which was $30.11 million.
The return on equity for the company, which belonged to Deciphera Pharmaceuticals, was a negative 74.37%, and the net margin was a negative 231.90%. Both of these figures were negative. The company’s sales increased 37.8 percent compared to the previous fiscal year. The company incurred a loss of $1.2 per share over the same period in the prior year. The majority opinion of experts covering the pharmaceuticals business is that Deciphera Pharmaceuticals will end the current financial year with a loss of -2.44 cents per share. In recent months, several institutional investors, including hedge funds and other types of funds, have modified the stakes they already hold in the company. US Bancorp DE boosted the amount of its investment in Deciphera Pharmaceuticals by 100.6% during the second quarter of the fiscal year. US Bancorp DE now holds 4,052 shares of the company’s stock following the acquisition of an additional 2,032 shares during the quarter. Each share of the company’s stock has a current market value of $53,000. Amalgamated Bank contributed approximately $57,000 to Deciphera Pharmaceuticals as part of a new investment made in the company during the first three months of 2018. During the first three months of 2018, Lazard Asset Management LLC started a new position in Deciphera Pharmaceuticals by investing roughly $57,000 in the company. Over the year’s first three months, Denali Advisors LLC successfully increased its holdings in Deciphera Pharmaceuticals by 33.9%. Denali Advisors LLC is now the owner of 7,900 shares of the company’s stock, which are worth $73,000 at the current market price.
This comes about directly from the most recent acquisition of 2,000 additional shares by the corporation during the most recent quarter. Last but not least, throughout the first quarter, Los Angeles Capital Management LLC boosted its holdings in Deciphera Pharmaceuticals by increasing its share count by purchasing new shares for close to $98,000. Institutional investors and hedge funds jointly control 87.97% of the firm’s total shares, which means that these two types of investors hold the bulk of the company’s stock. Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm that develops medications to address the primary mechanisms of drug resistance. This extends and accelerates the response to traditional cancer therapy in the United States and worldwide. The corporation, Deciphera Pharmaceuticals, Inc., is responsible for developing these medicinal products. The company’s primary therapeutic candidate is QINLOCK, and it is now being investigated as part of a research effort called INTRIGUE Phase 3 for treating second-line gastrointestinal stromal tumors (GIST).
